Investigational drug · Phase 3
SHR-1501
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Papillary-Only Non-muscle-invasive Bladder Cancer, Patients With Advanced or Metastatic Malignant Tumors, NMIBC.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 8, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
7
Any phase or sponsor naming "SHR-1501"
First trial start
2022
Nov 23, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SHR-1501", any sponsor or status.
Conditions studied
As listed on its trial records.
- Papillary-Only Non-muscle-invasive Bladder Cancer
- Patients With Advanced or Metastatic Malignant Tumors
- NMIBC
- High-risk NMIBC
Approved drugs for the same conditions: Bladder and urothelial cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "SHR-1501" as an intervention, largest first.
- A Study of SHR-1501 Combination With BCG Versus Placebo Combined With BCG in Subjects With Papillary-Only NMIBCPivotal-lookingRecruiting
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
NCT07726992 · 750 participants (planned) · Start Aug 25, 2026 · Primary completion Dec 2029
Drug: SHR-1501+BCG; Placebo +BCG · For: Papillary-Only Non-muscle-invasive Bladder Cancer
Sites: Beijing, China; Guangzhou, China
- A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBCPivotal-lookingRecruiting
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
NCT07424287 · 236 participants (planned) · Start Jul 13, 2026 · Primary completion Jun 2030
Drug: SHR-1501 for Injection; BCG for Injection and 5 more · For: NMIBC
Sites: Beijing, China; Shanghai, China
- Phase I/II Clinical Study of SHR-1501 Combined With Adbelizumab in Patients With Malignant TumorsRecruiting
Shanghai Hengrui Pharmaceutical Co., Ltd.Industry
NCT07073534 · 203 participants (planned) · Start Jul 24, 2025 · Primary completion Dec 2027
Drug: SHR-1501, Adebrelimab · For: Patients With Advanced or Metastatic Malignant Tumors
Sites: Guangzhou, China
Shanghai Hengrui Pharmaceutical Co., Ltd.Industry
NCT05410730 · 150 participants (planned) · Start Nov 23, 2022 · Primary completion May 2025
Drug: SHR-1501 · For: High-risk NMIBC
Sites: Beijing, China
- SHR-1501 Combined With SHR-2005 for High-Risk Non-Muscle Invasive Bladder Cancer Which is Not Completely Resectable by TURBtNot yet recruiting
Fudan UniversityAcademic, hospital or other
NCT06588179 · 58 participants (planned) · Start Oct 1, 2024 · Primary completion Oct 1, 2027
Drug: SHR-1501+SHR-2005 · For: NMIBC
Sites: Shanghai, China
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT04025957 · 19 participants · Start Oct 30, 2019 · Primary completion Jul 31, 2022
Drug: SHR-1501 · For: Advanced Malignancies
Sites: Beijing, China
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT03995472 · 14 participants · Start Feb 14, 2020 · Primary completion Jan 12, 2023
Drug: SHR-1501; SHR-1316 · For: Advanced Malignancies
Sites: Liverpool, Australia; Randwick, Australia; South Brisbane, Australia · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- IL-15 Superagonist SHR-1501 Enhances Immune Responses in Lung Cancer by Modulating Tumor Microenvironment.
Zhang Q, Hu C, Jiang M, et al. · Clin Respir J 2025
Also in development for Papillary-Only Non-muscle-invasive Bladder Cancer
- BCGPhase 38 trials
ImmunityBio, Inc. · Non-muscle Invasive Bladder Cancer (NMIBC), Papillary-Only Non-muscle-invasive Bladder Cancer, Tuberculosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.